acetogenins and Uterine-Cervical-Neoplasms

acetogenins has been researched along with Uterine-Cervical-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for acetogenins and Uterine-Cervical-Neoplasms

Article	Year
Antiproliferative Activity of Mycalin A and Its Analogues on Human Skin Melanoma and Human Cervical Cancer Cells. Marine drugs, 2020, Jul-29, Volume: 18, Issue:8 Mycalin A, a polybrominated C Topics: Acetogenins; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Female; HeLa Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Melanoma; Molecular Structure; Porifera; Skin Neoplasms; Structure-Activity Relationship; Uterine Cervical Neoplasms	2020
Folate-targeting annonaceous acetogenins nanosuspensions: significantly enhanced antitumor efficacy in HeLa tumor-bearing mice. Drug delivery, 2018, Volume: 25, Issue:1 Annonaceous acetogenins (ACGs) are one of the most active constituents isolated from Annona species with potent antitumor activity. However, the poor solubility and severe side effect greatly limit their use in clinic. In this study, folic acid (FA) modified annonaceous acetogenins nanosuspensions (FA-PEG-ACGs-NSps) had been successfully prepared using DSPE-PEG-FA and soybean lecithin (SPC) as stabilizers. The resultant FA-PEG-ACGs-NSps had a mean particle size of 119.7 nm, a zeta potential of -23.0 mV and a high drug payload of 49.68%. The obtained ACGs-NSps had a good stability in various physiological media, and showed sustained drug release. Compared to common ACGs nanoparticles (PEG-ACGs-NSps), FA-PEG-ACGs-NSps showed significantly enhanced in vitro cytotoxicity against folate receptor-positive HeLa cell lines (IC50, 0.483 μg/mL vs. 0.915 μg/mL, p < .05), which could be effectively reversed simply by pretreatment of free FA. In vivo experiments demonstrated that FA-PEG-ACGs-NSps brought more drug molecules into tumors and greatly improved the antitumor efficacy (TIR, 76.45% vs. 25.29%, p < .001). Therefore, DSPE-PEG-FA is considered as a proper stabilizer with active targeting effect for ACGs-NSps to reduce toxicity, enlarge the safe dosage range and apply in clinic for the treatment of folate-positive tumors. Therefore, FA-PEG-ACGs-NSps may be a prospective drug delivery system for ACGs to improve their therapeutic window and find application in clinic to treat FR over-expressed tumors. Topics: Acetogenins; Animals; Antineoplastic Agents, Phytogenic; Cell Proliferation; Dose-Response Relationship, Drug; Drug Compounding; Drug Liberation; Excipients; Female; Folic Acid; Folic Acid Transporters; HeLa Cells; Humans; Lecithins; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Particle Size; Phosphatidylethanolamines; Polyethylene Glycols; Solubility; Technology, Pharmaceutical; Time Factors; Tumor Burden; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays	2018

Article

Year

Antiproliferative Activity of Mycalin A and Its Analogues on Human Skin Melanoma and Human Cervical Cancer Cells.

Marine drugs, 2020, Jul-29, Volume: 18, Issue:8

Mycalin A, a polybrominated C

Topics: Acetogenins; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Female; HeLa Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Melanoma; Molecular Structure; Porifera; Skin Neoplasms; Structure-Activity Relationship; Uterine Cervical Neoplasms

2020

Folate-targeting annonaceous acetogenins nanosuspensions: significantly enhanced antitumor efficacy in HeLa tumor-bearing mice.

Drug delivery, 2018, Volume: 25, Issue:1

Annonaceous acetogenins (ACGs) are one of the most active constituents isolated from Annona species with potent antitumor activity. However, the poor solubility and severe side effect greatly limit their use in clinic. In this study, folic acid (FA) modified annonaceous acetogenins nanosuspensions (FA-PEG-ACGs-NSps) had been successfully prepared using DSPE-PEG-FA and soybean lecithin (SPC) as stabilizers. The resultant FA-PEG-ACGs-NSps had a mean particle size of 119.7 nm, a zeta potential of -23.0 mV and a high drug payload of 49.68%. The obtained ACGs-NSps had a good stability in various physiological media, and showed sustained drug release. Compared to common ACGs nanoparticles (PEG-ACGs-NSps), FA-PEG-ACGs-NSps showed significantly enhanced in vitro cytotoxicity against folate receptor-positive HeLa cell lines (IC50, 0.483 μg/mL vs. 0.915 μg/mL, p < .05), which could be effectively reversed simply by pretreatment of free FA. In vivo experiments demonstrated that FA-PEG-ACGs-NSps brought more drug molecules into tumors and greatly improved the antitumor efficacy (TIR, 76.45% vs. 25.29%, p < .001). Therefore, DSPE-PEG-FA is considered as a proper stabilizer with active targeting effect for ACGs-NSps to reduce toxicity, enlarge the safe dosage range and apply in clinic for the treatment of folate-positive tumors. Therefore, FA-PEG-ACGs-NSps may be a prospective drug delivery system for ACGs to improve their therapeutic window and find application in clinic to treat FR over-expressed tumors.

Topics: Acetogenins; Animals; Antineoplastic Agents, Phytogenic; Cell Proliferation; Dose-Response Relationship, Drug; Drug Compounding; Drug Liberation; Excipients; Female; Folic Acid; Folic Acid Transporters; HeLa Cells; Humans; Lecithins; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Particle Size; Phosphatidylethanolamines; Polyethylene Glycols; Solubility; Technology, Pharmaceutical; Time Factors; Tumor Burden; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays

2018